Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp
Bullboard Posts
User Avatar Image
(0)
•••
Post by slaveonfoolson Jun 11, 2013 9:42am
169 Views
Post# 21510304

Number 16

Number 16

Biggest life sciences companies in B.C. in 2012

Print

RANKED BY | Ranked by number of R&D employees in 2012

Rank '13 Company Areas of research Ownership Year founded No. staff globally '12/'11 No. BC staff '12/'11 No. R&D staff '12/'11
1 STEMCELL Technologies Inc
www.stemcell.com		 Stem cell biology focused on hematology, immunology, neurobiology, breast, prostate, pancreas, regenerative medicine and tissue engineering Privately held
Allen Eaves		 1993 521
399		 411
323		 137
110
2 Kardium Inc
www.kardium.com		 Cardiovascular Privately held 2007 60
47		 60
47		 55
40
3 Amgen British Columbia Inc
www.amgen.com		 Antibody therapeutics for the treatment of oncology, inflammation and infectious diseases Nasdaq:AMGN
Amgen Inc		 1980 17,000
17,000		 65
65		 50
50
4 Xenon Pharmaceuticals Inc
www.xenon-pharma.com		 Metabolic, neurological and cardiovascular Privately held 1996 NP
66		 NP
66		 471
47
5 Tekmira Pharmaceuticals Corp
www.tekmirapharm.com		 RNA interference (RNAi) therapeutics TSX:TKM; Nasdaq:TKMR
Widely held		 1992 63
80		 63
79		 402
67
6 QLT Inc
www.qltinc.com		 Ocular Nasdaq:QLTI, TSX:QLT
Widely held		 1981 68
175		 60
140		 39
82
7 Zymeworks Inc
www.zymeworks.com		 Antibody and protein therapeutics development for oncology, autoimmunity and anti-inflammation applications Privately held 2003 42
37		 42
37		 34
31
8 ABM Applied Biological Materials Inc
www.abmgood.com		 Expression libraries for ORF, siRNA and miRNA; lentivirus and adenovirus systems; cell immortalization; stem cells; next generation sequencing Privately held
Peter Li		 2004 57
NP		 37
NP		 27
NP
9 Angiotech Pharmaceuticals Inc3
www.angiotech.com		 Treatment solutions for diseases/complications associated with medical device implants, surgical interventions, acute injury Privately held3
Privately held		 1992 NP
1,0302		 NP
752		 202
352
10 Kinexus Bioinformatics Corporation
www.kinexus.ca		 Proteomics and bioinformatics products and services Privately held
Dr. Steven Pelech		 1999 16
18		 16
18		 13
15
11 Aquinox Pharmaceuticals Inc
www.aqxpharma.com		 Novel targeted small molecule therapeutics for the treatment of inflammatory disease Privately held 2006 20
27		 20
27		 12
22
12 Neova Technologies Inc
www.neovatech.com		 Downstream protein purification for food, nutraceuticals, pharmaceuticals; protein conjugations; bioprotection (food protection, human and animal health) Privately held 1982 NP
114		 NP
52		 111
11
12 Neovasc Inc
www.neovasc.com		 Develops, manufactures and markets innovative vascular devices offering pericardial tissue processing, vascular product development, design and manufacturing solutions to industry parterners. We have a comprehensive R&D laboratory and team that develop pericardial tissue-based devices, catheter-based devices and engineered heart valves. TSX-V:NVC
TSX-V:NVC		 2000 81
49		 81
47		 111
11
14 OncoGenex Pharmaceuticals
www.oncogenex.com		 Development of novel therapeutics that address treatment-resistant and metastatic cancer Nasdaq:OGXI 2000 32
264		 NP
104		 94
94
15 Qu Biologics Inc
www.qubiologics.com		 Treatment of chronic inflammatory conditions including cancer, inflammatory bowel disease (IBD: Crohn's disease and ulcerative colitis) and arthritis Privately held
Hal Gunn		 2007 9
9		 9
9		 8
6
16 Sirona Biochem Corp
www.sironabiochem.com		 Diabetes and obesity therapeutics, cancer vaccine antigen, cosmeceuticals, biological ingredients TSX-V:SBM 2006 14
13		 6
6		 8
1
17 Alectos Therapeutics
www.alectos.com		 Neuroscience, oncology Privately held 2007 NP
NP		 NP
NP		 8
NP
18 Sirius Genomics Inc
www.siriusgenomics.com		 Drug reprofiling company; focus on pharmacogenomic diagnostics Privately held
BC Advantage Funds		 2001 10
10		 10
10		 71
7
19 MSI Methylation Sciences Inc
www.methylationsciences.com		 Depression Privately held 2007 NP
NP		 NP
NP		 7
64
20 Celator Pharmaceuticals
www.celatorpharma.com		 Cancer therapies Privately held
venture capital		 2000 NP
17		 NP
9		 51
5
21 PNP Pharmaceuticals Inc
www.pnppharmaceuticals.com		 Nutraceutical, OTC OD tablets Private 1999 110
NP		 110
NP		 5
NP
22 enGene Inc
www.engeneinc.com		 Delivery of biologics to the intestine to treat autoimmune (inflammatory bowel disease) and metabolic diseases (diabetes) Privately held 1999 NP
5		 NP
5		 41
4
23 biOasis Technologies Inc
www.bioasis.ca		 Technologies and products intended for diagnosis and treatment of central nervous system (“CNS”) diseases and other disorders located within the brain. Publicly held
TSX-V:BTI		 2006 7
5		 6
5		 3
55
Sources: Interviews with representatives of the above biotech firms and BIV research. NR Not ranked NP Not provided 1 - 2011 figure 2 - BIV estimate 3 - Acquired by debt holders after filing creditor protection in January 2011 4 - 2010 figure 5 - 2009 figure

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities